Long lasting fusion peptide inhibitors of viral infection

Details Long lasting fusion peptide inhibitors of viral infection Long lasting fusion peptide inhibitors of viral infection

2006-08-15

2006-08-15

Parkin, Jeffrey S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S193100, C424S188100, C424S208100

Reexamination Certificate

active

07090851

ABSTRACT:
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.

REFERENCES:
patent: 4652629 (1987-03-01), Patrick et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5614487 (1997-03-01), Battersby et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6103236 (2000-08-01), Suzawa et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 0602290 (1994-06-01), None
patent: 9510302 (1995-04-01), None
patent: 96/19495 (1996-06-01), None
patent: WO 96/19495 (1996-06-01), None
patent: 9924074 (1999-05-01), None
patent: 9924075 (1999-05-01), None
patent: 9948536 (1999-09-01), None
patent: 00/76550 (2000-12-01), None
patent: 00/76551 (2000-12-01), None
Tolman, R. L., et al., 1993, “Cyclic V3-loop-related HIV-1 conjugate vaccines”, Int. J. Peptide Protein Res. 41:455-466.
Proc. Natl. Acad. Sci., 1996, 93 (5), 2186-2191.
Anti-Cancer Drugs, 1988, 8, 677-685.
U.S. Appl. No. 09/623,533, filed Sep. 2000, Bridon, et al.
Archakov, Alexander I. et al. (2003) “Protein-Protein Interactions as a Target for Drugs in Proteomics,” Proteomics, 3: 380-391.
Davies, David R. et al. (Jan. 1996) “Interactions of Protein Antigens with Antibodies,” Proc. Natl. Acad. Sci. USA, 93: 7-12.
Jiang, Shibo et al. (2002) “Peptide and Non-peptide HIV Fusion Inhibitors,” Current Pharmaceutical Design, 8: 563-580.
Jones, Susan et al. (Jan. 1996) “Principles of Protein-Protein Interactions,” Proc. Natl. Acad. Sci. USA, 93: 13-20.
Kwong, Peter D. et al. (Feb. 2000) “Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus,” Journal of Virology, 74(4): 1961-1972.
Kuiken, C. et al. ed.HIV Sequence Compendium 2001, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2002: 288-289.
Lawless, Mary K. et al. (1996) “HIV-1 Membrane Fusion Mechanism: Structural Studies of the Interactions between Biologically-Active Peptides from gp41,” Biochemistry, 35: 13697-13708.
Sanders, Rogier W. et al. (Sep. 2002) “Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1,” Journal of Virology, 76(17) 8875-8889.
Wang, Ning et al. (Apr. 1995) “Sequence Diversity of V1 and V2 Domains of gp120 from Human Immunodeficiency Virus Type 1: Lack of Correlation with Viral Phenotype,” Journal of Virology, 69(4): 2708-2715.
Yang, Xinzhen et al. (May 2000) “Modifications that Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution,” Journal of Virology, 74(10): 4746-4754.
Tolman, R.L. et al. (1993) “Cyclic V3-Loop-Related HIC-1 Conjugate Vaccines: Synthesis, Conformation and Immunological Properties”Int. J. Peptide Protein Res. 41: 455-466.
U.S. Appl. No. 10/950,010, filed Sep. 24, 2004, Bridon et al.
Christophe Boeckler, “Immunogenicity of New Heterobifunctional Cross-Linking Reagents Used in the Conjugation . . . ”, Journal of Immunological Methods, 1996, vol. 191, pp. 1-10.
Carl Wild, “A synthetic Peptide Inhibitor of Human Immunodeficiency Virus Replication : Correlation . . . ”, Proc. Natl. Acad. Sci., Nov. 1992, vol. 89, pp. 10537-10541.
Joseph G. Sodroski, “HIV-1 Entry Inhibitors in the Side Pocket”, Cell, Oct. 29, 1999, vol. 99, pp. 243-246.
Aran F. Labrijn, “Access of Antibody Molecules to the Conversed Coreceptor Binding Site on Glycoprotein gp120 . . . ” Journal of Virology, Oct. 2003, vol. 77, pp. 10557-10565.
Nasar M. Qureshi, “Characterization of a Putative Cellular Receptor for HIV-1 Transmembrane Glycoprotein Using Synthetic Peptides” AIDS, 1990, vol. 4, pp. 553-558.
Chen, Chin-Ho et al. (Jun. 1995) “A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion,” Journal of Virology, 69(6): 3771-3777.
Shugars, Diane C. et al. (May 1996) “Biophysical Characterization of Recombinant Proteins Expressing the Leucine Zipper-Like Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41,” Journal of Virology, 70(5): 2982-2991.

Affiliated with

Also associated with

Rating

Long lasting fusion peptide inhibitors of viral infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Long lasting fusion peptide inhibitors of viral infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long lasting fusion peptide inhibitors of viral infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3675154